Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 6, 2014, Pages 840-851

  Cardama, Georgina A ^a   Comin, Maria J ^b   Hornos, Leandro ^b   Gonzalez, Nazareno ^a   Defelipe, Lucas ^c   Turjanski, Adrian G ^c   Alonso, Daniel F ^a   Gomez, Daniel E ^a   Menna, Pablo Lorenzano ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b INSTITUTO NACIONAL DE TECNOLOGÍA INDUSTRIAL   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Breast cancer; Docking; Rac1 inhibitor; Rational design; Virtual screening

Indexed keywords

1A 116; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL] AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ACTIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PEPTIDES AND PROTEINS; RAC1 PROTEIN; TIAM1 PROTEIN; UNCLASSIFIED DRUG; ZINC69391; GUANIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RAC1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOASSAY; BREAST CANCER; CELL CYCLE ASSAY; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULAR DOCKING; MOUSE; MTT ASSAY; NONHUMAN; PRECIPITATION; PROTEIN INTERACTION; PULL DOWN ASSAY; SCREENING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GUANIDINES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84904128480     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113136660334     Document Type: Article

References (70)

1. Etienne-Manneville, S.; Hall, A. Rho GTPases in cell biology. Nature, 2002, 420(6916), 629-635.
2. Bishop, A.L.; Hall, A. Rho GTPases and their effector proteins. Biochem. J., 2000, 348(Pt 2), 241-55.
3. Bosco, E.E.; Mulloy, J.C.; Zheng, Y. Rac1 GTPase: a Rac of all trades. Cell Mol. Life Sci., 2009, 66(3), 370-374.
4. Ellenbroek, S.I.; Collard, J.G. Rho GTPases: Functions and association with cancer. Clin. Exp. Metastasis, 2007, 24(8), 657-672.
5. Fritz, G.; Just, I.; Kaina, B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer, 1999, 81(5), 682-687.
6. Fritz, G.; Brachetti, C.; Bahlmann, F.; Schmidt, M.; Kaina, B. Rho GTPases in human breast tumours: Expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer, 2002, 87(6), 635-644.
7. Kamai, T.; Yamanishi, T.; Shirataki, H.; Takagi, K.; Asami, H.; Ito, Y.; Yoshida, K. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin. Cancer Res., 2004, 10, 4799-4805.
8. Buongiorno, P. and Bapat, B. Rho GTPases and cancer. Prog. Mol. Subcell. Biol., 2005, 40, 29-53.
9. Schnelzer, A.; Prechtel, D.; Knaus, U.; Dehne, K.; Gerhard, M.; Graeff, H.; Harbeck, N.; Schmitt, M.; Lengyel, E. Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene, 2000, 19(26), 3013-3020.
10. Khosravi-Far, R.; Solski, P.A.; Clark, G.J.; Kinch, M.S.; Der, C.J. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol., 1995, 15, 6443-6453.
11. Fritz, G. and Kaina, B. Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr. Cancer Drug Targets, 2006, 6(1), 1-1.
12. Vigil, D.; Cherfils, J.; Rossman, K.L.; Der, C.J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer, 2010, 10(12), 842-857.
13. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.; Goh, G.; Choi, M.; Ariyan, S.; Narayan, D.; Dutton-Regester, K.; Capatana, A.; Holman, E.C.; Bosenberg, M.; Sznol, M.; Kluger, H.M.; Brash, D.E.; Stern, D.F.; Materin, M.A.; Lo, R.S.; Mane, S.; Ma, S.; Kidd, K.K.; Hayward, N.K.; Lifton, R.P.; Schlessinger, J.; Boggon, T.J.; Halaban, R. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet., 2012, 44(9), 1006-1014.
14. Hodis E.; Watson I.R.; Kryukov G.V.; Arold S.T.; Imielinski M.; Theurillat J.P.; Nickerson E.; Auclair D.; Li L.; Place C.; Dicara D.; Ramos A.H.; Lawrence M.S.; Cibulskis K.; Sivachenko A.; Voet D.; Saksena G.; Stransky N.; Onofrio R.C.; Winckler W.; Ardlie K.; Wagle N.; Wargo J.; Chong K.; Morton D.L.; Stemke-Hale K.; Chen G.; Noble M.; Meyerson M.; Ladbury J.E.; Davies M.A.; Gershenwald J.E.; Wagner S.N.; Hoon D.S.; Schadendorf D.; Lander E.S.; Gabriel S.B.; Getz G.; Garraway L.A.; Chin L. A landscape of driver mutations in melanoma. Cell, 2012, 150(2), 251-263.
15. Rossman K.L.; Der, C.J.; Sondek, J. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol., 2005, 6(2), 167-180.
16. Fields, A.P. and Justilien, V. The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancer. Adv. Enzyme Regul., 2010, 50(1), 190-200.
17. Van Leeuwen, F.N.; Van der Kammen, R.A.; Habets, G.G.; Collard, J.G. Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells. Oncogene, 1995, 11(11), 2215-2221.
18. Gao, Y.; Xing, J.; Streuli, M.; Leto, T.L.; Zheng, Y. Trp(56) of rac1 specifies interaction with a subset of guanine nucleotide exchange factors. J. Biol. Chem., 2001, 276(50), 47530-47541.
19. Karnoub, A.E.; Worthylake, D.K.; Rossman, K.L.; Pruitt, W.M.; Campbell, S.L.; Sondek, J.; Der, C.J. Molecular basis for Rac1 recognition by guanine nucleotide exchange factors. Nat. Struct. Biol., 2001, 8(12), 1037-1041.
20. Wu, X.; Ramachandran, S.; Lin, M.C.; Cerione, R.A.; Erickson, J.W. A minimal Rac activation domain in the unconventional guanine nucleotide exchange factor Dock180. Biochemistry, 2011, 50(6), 1070-80.
21. Shoichet, B.K. Virtual screening of chemical libraries. Nature, 2004, 432(7019), 862-865.
22. Cosconati, S.; Forli, S.; Perryman, A.L.; Harris, R.; Goodsell, D.S.; Olson, A.J. Virtual screening with autodock: Theory and practice. Expert Opin. Drug Discov., 2010, 5(6), 597-607.
23. Irwin, J.J.; Shoichet, B.K. ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005, 45(1), 177-182.
24. Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A free tool to discover chemistry for biology. J. Chem. Inf. Model, 2012, 52(7), 1757-1768.
25. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, SB.; Johnson, A.P. eHiTS: A new fast, exhaustive flexible ligand docking system. J. Mol. Graph Model, 2007, 26(1), 198-212.
26. Morris, G.M.; Huey, R.; Olson, A.J. Using AutoDock for ligandreceptor docking. Curr. Protoc. Bioinformatics, 2008 Chapter 8:Unit 8.14.
27. Alonso, D.F.; Farías, E.F.; Urtreger, A.; Ladeda, V.; Vidal, M.C.; Bal De Kier, Joffé, E. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J. Surg. Oncol., 1996, 62(4), 288-297.
28. Best, A.; Ahmed, S.; Kozma R.; Lim L. The Ras-related GTPase Rac1 binds tubulin. J. Biol. Chem., 1996, 271(7), 3756-3762.
29. Habets, G.G.; Scholtes, E.H.; Zuydgeest, D.; Van Der Kammen, R.A.; Stam, J.C.; Berns, A.; Collard, J.G. Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell, 1994, 77(4), 537-549.
30. Stam, J.C.; Sander, E.E.; Michiels, F.; Van Leeuwen, F.N.; Kain, H.E.; Van der Kammen, R.A.; Collard, J.G. Targeting of Tiam1 to the plasma membrane requires the cooperative function of the Nterminal pleckstrin homology domain and an adjacent protein interaction domain. J. Biol. Chem., 1997, 272(45), 28447-28454.
31. Sosa, M.S.; Lopez-Haber, C.; Yang, C.; Wang, H.; Lemmon, M.A.; Busillo, J.M.; Luo, J.; MBenovic, J.L.; Klein-Szanto, A.; Yagi, H.; Gutkind, J.S.; Parsons, R.E.; Kazanietz, M.G. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol. Cell, 2011, 40, 877.
32. Segatori, V.I.; Otero, L.L.; Fernandez, L.E.; Gomez, D.E.; Alonso, D.F.; Gabri, M.R. Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. In vivo 2012, 26(4), 609-617.
33. National Institute of Health (NIH). Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity. NIH Publication No: 01-4500, 2001.
34. Fanger, G.R.; Johnson, N.L.; Johnson, G.L. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J., 1997, 16(16), 4961-4972.
35. Itoh, R.E.; Kiyokawa, E.; Aoki, K.; Nishioka, T.; Akiyama, T.; Matsuda, M. Phosphorylation and activation of the Rac1 and Cdc42 GEF Asef in A431 cells stimulated by EGF. J. Cell Sci., 2008, 121(Pt 16), 2635-2642.
36. Menna, P.L.; Skilton, G.; Leskow, F.C.; Alonso, D.F.; Gomez, D.E.; Kazanietz, M.G. Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain. Cancer Res., 2003, 63(9), 2284-2291.
37. Snyder, J.T.; Worthylake, D.K.; Rossman, K.L.; Betts L.; Pruitt, W.M.; Siderovski, D.P.; Der, C.J.; Sondek, J. Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. Nat. Struct. Biol., 2002, 9(6), 468-475.
38. Yang, C.; Liu, Y.; Leskow, F.C.; Weaver, V.M.; Kazanietz, M.G. Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin. J. Biol. Chem., 2005, 280(26), 24363-24370.
39. Montalvo-Ortiz, B.L.; Castillo-Pichardo, L.; Hernández, E.; Humphries-Bickley, T.; De la Mota-Peynado A.; Cubano, L.A.; Vlaar, C.P.; Dharmawardhane, S. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J. Biol. Chem., 2012, 287(16), 13228-13238.
40. Yoshida, T.; Zhang, Y.; Rivera Rosado, L.A.; Chen, J.; Khan, T.; Moon, S.Y.; Zhang, B. Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein. Mol. Cancer Ther., 2010, 9(6), 1657-1668.
41. Hall, A. Rho GTPases and the actin cytoskeleton. Science, 1998, 279(5350), 509-514.
42. Ridley; A.J. Rho GTPases and cell migration. J. Cell Sci., 2001, 114(Pt 15), 2713-2722.
43. Li, S.; Wang, Q.; Wang, Y.; Chen, X.; Wang, Z. PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration Mol. Endocrinol., 2009, 23(6), 901-913.
44. Tetko, I.V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V.A.; Radchenko, E.V.; Zefirov, N.S.; Makarenko, A.S.; Tanchuk, V.Y.; Prokopenko, V.V. Virtual computational chemistry laboratory -design and description. J. Comput. Aid. Mol. Des., 2005, 19(6), 453-463.
45. Montero, J.C.; Seoane, S.; Ocana, A.; Pandiella, A. P-Rex1 participates in Neuregulin-ErbB signaltransduction and its expression correlates with patient outcome in breast cancer. Oncogene, 2011, 30, 1059-1071.
46. Han, S.S.R.; Cho, C.K.; Lee, Y.W.; Yoo, H.S. Antimetastatic and immunomodulating effect of water extracts from various mushrooms. J. Acupunct. Meridian Stud., 2009, 2(3), 218-227.
47. Ma, J.; Xue, Y.; Liu, W.; Yue, C.; Bi, F.; Xu, J.; Zhang, J.; Li, Y.; Zhong, C.; Chen, Y. Role of activated rac1/cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer. PLoS One, 2013, 8(6), e66275.
48. Katz, E.; Sims, A.H.; Sproul, D.; Caldwell, H.; Dixon, M.J.; Meehan, R.R.; Harrison, D.J. Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget, 2012, 3(6), 608-619.
49. Jordan, P.; Brazåo, R.; Boavida, M.G.; Gespach, C.; Chastre, E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene, 1999, 18(48), 6835-6839.
50. Radisky, D.C; Levy, D.D; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; Werb, Z.; Bissell, M.J. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005, 436(7047), 123-127.
51. Singh, A.; Karnoub, A.E.; Palmby, T.R.; Lengyel, E.; Sondek, J.; Der, C.J. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene, 2004, 23(58), 9369-9380.
52. Herter-Sprie, G.S.; Greulich, H.; Wong, K.K. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front. Oncol. 2013, 3, 86.
53. Saini, K.S.; Loi S.; de Azambuja, E.; Metzger-Filho, O.; Saini, M.L.; Ignatiadis, M., Dancey, J.E.; Piccart-Gebhart, M.J. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat. Rev., 2013, 39(8):935-946.
54. Jhaveri, K.; Modi, S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv. Pharmacol., 2012, 65, 471-517.
55. Aznar, S.; Fernández-Valerón, P.; Espina, C.; Lacal, J.C. Rho GTPases: Potential candidates for anticancer therapy. Cancer Lett., 2004, 206(2), 181-191.
56. Wang, C.Y.; Liu, P.Y.; Liao, J.K. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14(1), 37-44.
57. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest., 2003, 111(8), 1133-1145.
58. Poppe, D.; Tiede, I.; Fritz, G.; Becker, C.; Bartsch, B.; Wirtz, S.; Strand, D.; Tanaka, S.; Galle, P.R.; Bustelo, X.R.; Neurath, M.F. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol., 2006, 176(1), 640-651.
59. Menna, P.L.; Parera, R.L.; Cardama, G.A.; Alonso, D.F.; Gomez, D.E.; Farina, H.G. Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing β2-chimaerin. Mol. Med. Report, 2009, 2(1), 97-102.
60. Gao, Y.; Dickerson, J.B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA. 2004, 101(20), 7618-7623.
61. Ferri, N.; Corsini, A.; Bottino, P.; Clerici, F.; Contini, A. Virtual screening approach for the identification of new Rac1 inhibitors. J. Med. Chem., 2009, 52(14), 4087-4090.
62. Hernández, E.; De La Mota-Peynado, A.; Dharmawardhane, S.; Vlaar, C.P. Novel inhibitors of Rac1 in metastatic breast cancer. P R Health Sci. J., 2010, 29(4), 348-356.
63. Vives, V.; Laurin, M.; Cres, G.; Larrousse, P.; Morichaud, Z.; Noel, D.; Côté, J.F.; Blangy, A. The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts. J. Bone Miner. Res., 2011, 26(5), 1099-1110.
64. Bouquier, N.; Vignal, E.; Charrasse, S.; Weill, M.; Schmidt, S.; Léonetti, J.P.; Blangy, A.; Fort, P. A cell active chemical GEF inhibitor selectively targets the Trio/RhoG/Rac1 signaling pathway. Chem. Biol., 2009, 16(6), 657-666.
65. Blangy, A.; Bouquier, N.; Gauthier-Rouvière, C.; Schmidt, S.; Debant, A.; Leonetti, J.P.; Fort, P. Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. Biol. Cell, 2006, 98(9), 511-522.
66. Shutes, A.; Onesto, C.; Picard, V.; Leblond, B.; Schweighoffer, F.; Der, C.J. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem., 2007, 282(49), 35666-35678.
67. Bosco, E.E.; Kumar, S.; Marchioni, F.; Biesiada, J.; Kordos, M.; Szczur, K.; Meller, J.; Seibel, W.; Mizrahi, A.; Pick, E.; Filippi, M.D.; Zheng, Y. Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. Chem. Biol., 2012, 19(2), 228-242.
68. Murray, B.W.; Guo, C.; Piraino, J.; Westwick, J.K.; Zhang, C.; Lamerdin, J.; Dagostino, E.; Knighton, D.; Loi, C.M.; Zager, M.; Kraynov, E.; Popoff, I.; Christensen, J.G.; Martinez, R.; Kephart, S.E.; Marakovits, J.; Karlicek, S.; Bergqvist, S.; Smeal, T. Smallmolecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. USA. 2010, 107(20), 9446-9451.
69. Pearson, H.B.; Pouliot N. Modeling Metastasis In Vivo. In: Metastatic Cancer: Integrated Organ System and Biological Approach; Rahul Jandial and Kent Hunter, Ed.; Landes Bioscience. 2012.
70. Wertheimer, E.; Gutierrez-Uzquiza, A.; Rosemblit, C.; Lopez-Haber, C.; Sosa, M.S.; Kazanietz MG. Rac signaling in breast cancer: A tale of GEFs and GAPs. Cell Signal, 2012, 24(2), 353-362.